Myotonic Dystrophy Type 1 or Steinert’s Disease

  • Vincenzo Romeo
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 724)


Myotonic Dystrophy Type 1 (DM1) is the most common worldwide autosomal dominant muscular dystrophy due to polynucleotide [CTG] n triplet expansion located on the 3′UTR of chromosome 19q13.3. A toxic gain-of-function of abnormally stored RNA in the nuclei of affected cells is assumed to be responsible for several clinical features of the disease. It plays a basic role in deregulating RNA binding protein levels and in several mRNA splicing processes of several genes, thus leading to the multisystemic features typical of DM1. In DM1, the musculoskeletal apparatus, heart, brain, eye, endocrine, respiratory and gastroenteric systems are involved with variable levels of severity. DM1 onset can be congenital, juvenile, adult or late. DM1 can be diagnosed on the grounds of clinical presentation (distal muscular atrophy and weakness, grip and percussion myotonia, ptosis, hatchet face, slurred speech, rhinolalia), EMG myotonic pattern, EKG (such as AV-blocks) or routine blood test abnormalities (such as increased CK values or hypogamma-globulinemia) and history of cataract. Its confirmation can come by DNA analysis. At present, only symptomatic therapy is possible and is addressed at correcting hormonal and glycemic balance, removing cataract, preventing respiratory failure and, above all, major cardiac disturbances. Efficacious therapies targeted at the pathogenic mechanism of DM1 are not yet available, while studies that seek to block toxic RNA intranuclear storage with specific molecules are still ongoing.


Neurodegenerative Disease Muscular Dystrophy Dorsal Raphe Nucleus Myotonic Dystrophy Routine Blood Test 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Harper PS. Myotonic dystrophy. Ed. W. B. Saunders, third edition.Google Scholar
  2. 2.
    Brook JD, McCurrach ME, Harley HG et al. Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3′ end of a transcript encoding a protein kinase family member. Cell 1992; 68:799–808.PubMedCrossRefGoogle Scholar
  3. 3.
    Liquori CL, Ricker K, Moseley ML et al. Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9. Science 2001; 293:864–867.PubMedCrossRefGoogle Scholar
  4. 4.
    Lavedan C, Hofmann-Radvanyi H, Shelbourne P et al. Myotonic dystrophy: size-and sex-dependent dynamics of CTG meiotic instability and somatic mosaicism. Am J Hum Genet 1993; 52:875–883.PubMedGoogle Scholar
  5. 5.
    Thornton CA, Griggs RC, Moxley RT 3rd. Myotonic dystrophy with no trinucleotide repeat expansion. Ann Neurol 1994; 35:269–272.PubMedCrossRefGoogle Scholar
  6. 6.
    Udd B, Krahe R, Wallgren-Pettersson C et al. Proximal myotonic dystrophy—a family with autosomal dominant muscular dystrophy, cataracts, hearing loss and hypogonadism: heterogeneity of proximal myotonic syndromes? Neuromusc Disord 1997; 7:217–228.PubMedCrossRefGoogle Scholar
  7. 7.
    Moxley RT 3rd, Meola G, Udd B et al. Report of the 84th ENMC workshop: PROMM (proximal myotonic myopathy) and other myotonic dystrophy-like syndromes: 2nd workshop. 13–15th October, 2000, Loosdrecht, The Netherlands. Neuromuscul Disord 2002; 12:306–317.PubMedCrossRefGoogle Scholar
  8. 8.
    New nomenclature and DNA testing guidelines for myotonic dystrophy type 1 (DM1). The International Myotonic Dystrophy Consortium. Neurology 2000; 54:1218–1221.Google Scholar
  9. 9.
    de Die-Smulders CE, Höweler CJ, Thijs C et al. Age and causes of death in adult-onset myotonic dystrophy. Brain 1998; 121:1557–1563.PubMedCrossRefGoogle Scholar
  10. 10.
    Reardon W, Newcombe R, Fenton I et al. The natural history of congenital myotonic dystrophy: mortality and long term clinical aspects. Arch Dis Child 1993; 68:177–181.PubMedCrossRefGoogle Scholar
  11. 11.
    Mathieu J, Boivin H, Meunier D et al. Assessment of a disease-specific muscular impairment rating scale in myotonic dystrophy. Neurology 2001; 56:336–340.PubMedGoogle Scholar
  12. 12.
    Mathieu J, Allard P, Gobeil G et al. Anesthetic and surgical complications in 219 cases of myotonic dystrophy. Neurology 49:1646–1650.Google Scholar
  13. 13.
    Melacini P, Buja G, Fasoli G et al. The natural history of cardiac involvement in myotoic dystrophy: an eight-year follow-up in 17 patients. Clin Cardiol 1988; 11:231–238.PubMedCrossRefGoogle Scholar
  14. 14.
    Romeo V, Pegoraro E, Ferrati C et al. Brain involvement in myotonic dystrophies: neuroimaging and neuropsychological comparative study in DM1 and DM2. J Neurol 2010; 257:1246–1255.PubMedCrossRefGoogle Scholar
  15. 15.
    Meola G, Sansone V. Cerebral involvement in myotonic dystrophies. Muscle Nerve 2007; 36:294–306.PubMedCrossRefGoogle Scholar
  16. 16.
    Mastrogiacomo I, Bonanni G, Menegazzo E et al. Clinical and hormonal aspects of male hypogonadism in myotonic dystrophy. Ital J Neurol Sci 1996; 17:59–65.PubMedCrossRefGoogle Scholar
  17. 18.
    Moxley RT, Corbett AJ, Minaker KL et al. Whole body insulin resistance of myotonic dystrophy. Ann Neurology 1984; 15:157–162.CrossRefGoogle Scholar
  18. 19.
    Dubowitz V. Muscle biopsy, 2nd edition. Philadelphia: WB Saunders, 1985.Google Scholar
  19. 21.
    Faustino NA, Cooper TA. Pre-mRNA splicing and human disease. Gen Develop 2003; 17:419–437.CrossRefGoogle Scholar
  20. 22.
    Day JW, Ranum LP. RNA pathogenesis of the myotonic dystrophies. Neuromusc Disord 2005; 15:5–16.PubMedCrossRefGoogle Scholar
  21. 23.
    Logigian EL, Martens WB, Moxley RT 4th et al. Mexiletine is an effective antimyotonia treatment in myotonic dystrophy type 1. Neurology 2010; 74:1441–1448.PubMedCrossRefGoogle Scholar
  22. 24.
    Griggs RC, Pandya S, Florence JM et al. Randomized controlled trial of testosterone in myotonic dystrophy. Neurology 1989; 39:219–222.PubMedGoogle Scholar
  23. 25.
    Moxley RT 3rd. Potential for growth factor treatment of muscle disease. Curr Opin Neurol 1994; 7:427–434.PubMedCrossRefGoogle Scholar
  24. 26.
    Vlachopapadopoulou E, Zachwieja JJ, Gertner JM et al. Metabolic and clinical response to recombinant human insulin-like growth factor I in myotonic dystrophy—a clinical research center study. J Clin Endocrinol Metab 1995; 80:3715–3723.PubMedCrossRefGoogle Scholar
  25. 27.
    Maas O, Paterson AS. Mental changes in families affected by Dystrophia Myotonica. Lancet 1937; 1:21–23.CrossRefGoogle Scholar
  26. 28.
    Annane D, Moore DH, Barnes PR et al. Psychostimulants for hypersomnia (excessive daytime sleepiness) in myotonic dystrophy. Cochrane Database Syst Rev. 2002; 4:CD003218.PubMedGoogle Scholar

Copyright information

© Landes Bioscience and Springer Science+Business Media 2012

Authors and Affiliations

  • Vincenzo Romeo
    • 1
  1. 1.Department of NeurosciencesUniversity of Padova, School of MedicinePadovaItaly

Personalised recommendations